These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 26094857)
1. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. van Bloemendaal L; Veltman DJ; Ten Kulve JS; Groot PF; Ruhé HG; Barkhof F; Sloan JH; Diamant M; Ijzerman RG Diabetes Obes Metab; 2015 Sep; 17(9):878-86. PubMed ID: 26094857 [TBL] [Abstract][Full Text] [Related]
2. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. van Bloemendaal L; IJzerman RG; Ten Kulve JS; Barkhof F; Konrad RJ; Drent ML; Veltman DJ; Diamant M Diabetes; 2014 Dec; 63(12):4186-96. PubMed ID: 25071023 [TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial. van Ruiten CC; Veltman DJ; Wijdeveld M; Ten Kulve JS; Kramer MHH; Nieuwdorp M; IJzerman RG Diabetes Obes Metab; 2022 Aug; 24(8):1588-1597. PubMed ID: 35491524 [TBL] [Abstract][Full Text] [Related]
5. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. ten Kulve JS; Veltman DJ; van Bloemendaal L; Barkhof F; Deacon CF; Holst JJ; Konrad RJ; Sloan JH; Drent ML; Diamant M; IJzerman RG Diabetologia; 2015 Dec; 58(12):2688-98. PubMed ID: 26385462 [TBL] [Abstract][Full Text] [Related]
6. Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption. Ten Kulve JS; Veltman DJ; van Bloemendaal L; Groot PF; Ruhé HG; Barkhof F; Diamant M; Ijzerman RG J Endocrinol; 2016 Apr; 229(1):1-12. PubMed ID: 26769912 [TBL] [Abstract][Full Text] [Related]
7. Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation. van Bloemendaal L; Veltman DJ; ten Kulve JS; Drent ML; Barkhof F; Diamant M; IJzerman RG Obesity (Silver Spring); 2015 Oct; 23(10):2075-82. PubMed ID: 26331843 [TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus. Bae JH; Choi HJ; Cho KIK; Kim LK; Kwon JS; Cho YM Diabetes Metab J; 2020 Apr; 44(2):248-259. PubMed ID: 31701698 [TBL] [Abstract][Full Text] [Related]
9. Progressive anticipation in behavior and brain activation of rats exposed to scheduled daily palatable food. Blancas A; González-García SD; Rodríguez K; Escobar C Neuroscience; 2014 Dec; 281():44-53. PubMed ID: 25255933 [TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial. Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Diamant M; Pieters-van den Bos IC; van Raalte DH; Cahen DL Diabetes Obes Metab; 2016 Mar; 18(3):281-8. PubMed ID: 26640129 [TBL] [Abstract][Full Text] [Related]
11. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Anderberg RH; Richard JE; Hansson C; Nissbrandt H; Bergquist F; Skibicka KP Psychoneuroendocrinology; 2016 Mar; 65():54-66. PubMed ID: 26724568 [TBL] [Abstract][Full Text] [Related]
12. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Rodriquez de Fonseca F; Navarro M; Alvarez E; Roncero I; Chowen JA; Maestre O; Gómez R; Muñoz RM; Eng J; Blázquez E Metabolism; 2000 Jun; 49(6):709-17. PubMed ID: 10877194 [TBL] [Abstract][Full Text] [Related]
13. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. Dickson SL; Shirazi RH; Hansson C; Bergquist F; Nissbrandt H; Skibicka KP J Neurosci; 2012 Apr; 32(14):4812-20. PubMed ID: 22492036 [TBL] [Abstract][Full Text] [Related]
14. Relation of reward from food intake and anticipated food intake to obesity: a functional magnetic resonance imaging study. Stice E; Spoor S; Bohon C; Veldhuizen MG; Small DM J Abnorm Psychol; 2008 Nov; 117(4):924-35. PubMed ID: 19025237 [TBL] [Abstract][Full Text] [Related]
15. Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior. Anderberg RH; Anefors C; Bergquist F; Nissbrandt H; Skibicka KP Physiol Behav; 2014 Sep; 136():135-44. PubMed ID: 24560840 [TBL] [Abstract][Full Text] [Related]
16. Hippocampal GLP-1 receptors influence food intake, meal size, and effort-based responding for food through volume transmission. Hsu TM; Hahn JD; Konanur VR; Lam A; Kanoski SE Neuropsychopharmacology; 2015 Jan; 40(2):327-37. PubMed ID: 25035078 [TBL] [Abstract][Full Text] [Related]
17. Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. Jerlhag E Brain Res; 2020 Jan; 1727():146562. PubMed ID: 31759971 [TBL] [Abstract][Full Text] [Related]
18. The role of orexin-A in food motivation, reward-based feeding behavior and food-induced neuronal activation in rats. Choi DL; Davis JF; Fitzgerald ME; Benoit SC Neuroscience; 2010 Apr; 167(1):11-20. PubMed ID: 20149847 [TBL] [Abstract][Full Text] [Related]
19. Combined stimulation of glucagon-like peptide-1 receptor and inhibition of cannabinoid CB1 receptor act synergistically to reduce food intake and body weight in the rat. Bojanowska E; Radziszewska E J Physiol Pharmacol; 2011 Aug; 62(4):395-402. PubMed ID: 22100840 [TBL] [Abstract][Full Text] [Related]
20. Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from the saliva of the Gila monster. Alves PL; Abdalla FMF; Alponti RF; Silveira PF Toxicon; 2017 Sep; 135():1-11. PubMed ID: 28579479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]